Figure 1. Participant Flow in Trial A and Trial B Assessing the Effect of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Patients With Iron-Deficiency Anemia.

^aSome potential study participants had more than 1 reason for exclusion.

^bOne patient randomized to ferric carboxymaltose was erroneously treated with iron isomaltoside and included in the iron isomaltoside safety analysis set.

^cThree patients randomized to ferric carboxymaltose were not treated and not included in the safety analysis set.